Xencor

Engineered antibody therapeutics

XNCR · Nasdaq · United States

Share price · XNCR

$34.39+8.98 (+35.34%) 3M

close as of 2026-11-18 · 24h delayed · vol 867K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when XNCR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+14.3%
  2. 26 Oct 2026+15.9%
  3. 18 Aug 2026+9.9%
  4. 30 Jul 2026+10.0%
  5. 20 Jul 2026+7.7%
  6. 17 Jul 2026+16.9%
  7. 8 Jul 2026+5.0%
  8. 22 Jun 2026+10.8%
  9. 1 May 2026+6.4%
  10. 5 Mar 2026-12.4%

Share of unusual movement by asset

For each asset, the share of XNCR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tafasitamab
events and moves
7shown from 8 days
XmAb819
events and moves
6shown from 8 days
XmAb942
events and moves
3shown from 8 days
Plamotamab
events and moves
1shown from 8 days
XmAb657
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—17%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—60%

Assets

(6 total)
6Total Assets
1Approved
0Phase 3 / Filed
5Phase 1–2 / Early
8Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Approved
CD19Monoclonal antibody
Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma
Large B-Cell Lymphoma
Phase 1/2
TL1AMonoclonal antibody
Inflammatory Bowel Disease
Ulcerative Colitis
Phase 1
CD20 x CD3Multispecific antibody
Rheumatoid Arthritis
Phase 1
Claudin 6 (CLDN6) x CD3Multispecific antibody
Ovarian Cancer
Phase 1
CD19 x CD3Multispecific antibody
Idiopathic Inflammatory Myopathies
Phase 1
ENPP3 x CD3Multispecific antibody
Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
August 2027 (1)
TafasitamabPhase 2Hematologic Malignancies
Est. primary completion 2027-08-29 · NCT06465433 · CT.gov ↗
What to watch
September 2027 (1)
TafasitamabPhase 2Immune Thrombocytopenia
Est. primary completion 2027-09-23 · NCT07104565 · CT.gov ↗
What to watch
December 2027 (1)
XmAb942Phase 1/2Ulcerative Colitis (UC)
Est. primary completion 2027-12 · NCT06619990 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
TafasitamabPhase 3DLBCL
Est. primary completion 2028-09 · NCT06521255 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 June 2026ApprovalTafasitamabJapan approval of Minjuvi with lenalidomide for relapsed/refractory DLBCL
JP, MHLW · Source ↗
5 January 2026Topline resultTafasitamabPhase 3 frontMIND of tafasitamab plus lenalidomide and R-CHOP met its primary endpoint
Incyte · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$117M$84M$65M+ $318M short-term inv.—$2.6M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$51M$72M$45M+ $333M short-term inv.$22M-$56M operating cash flowreport ↗
2026-Q1$4.5M$65M$542M+ $370M short-term inv.$129M-$68M operating cash flowreport ↗
2025-Q3$21M$54M$29M+ $358M short-term inv.$6.0M-$31M operating cash flowreport ↗
2025-Q2$44M$62M$45M+ $359M short-term inv.$31M-$36M operating cash flowreport ↗
2025-Q1$33M$59M$40M+ $381M short-term inv.$48M-$16M operating cash flowreport ↗
2024-Q3$11M$58M$29M+ $435M short-term inv.$45M-$26M operating cash flowreport ↗
2024-Q2$17M$62M$31M+ $449M short-term inv.$66M-$65M operating cash flowreport ↗
2024-Q1$13M$57M$31M+ $460M short-term inv.$68M-$55M operating cash flowreport ↗
2023-Q3$59M$65M$53M+ $413M short-term inv.$24M-$27M operating cash flowreport ↗
2023-Q2$46M$60M$35M+ $477M short-term inv.$22M-$38M operating cash flowreport ↗
2023-Q1$19M$64M$72M+ $476M short-term inv.$61M-$31M operating cash flowreport ↗
2022-Q3$27M$53M$53M+ $515M short-term inv.$33M-$1.2M operating cash flowreport ↗
2022-Q2$30M$47M$49M+ $436M short-term inv.$34M$44M operating cash flowreport ↗
2022-Q1$86M$48M$78M+ $278M short-term inv.—$5.8M operating cash flowreport ↗
2021-Q3$20M$51M$41M$40M-$39M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$126M$239M$54M+ $381M short-term inv.$23M-$135M operating cash flowreport ↗

For FY2025, Xencor reported revenue of $125.58M, up 13.7% YoY from $110.49M. R&D spend was $239.43M, up 5.2% YoY from $227.69M. Cash and equivalents totaled $54.36M, with a net loss of $91.92M and quarterly net burn of $91.92M.

During the year, Xencor presented initial Phase 1 data for XmAb819 in clear cell renal cell carcinoma and early efficacy data for XmAb541 in gynecologic and germ cell tumors, initiated a global Phase 2b study (XENITH-UC) of XmAb942 in ulcerative colitis after reporting healthy-volunteer data, started a Phase 1b proof-of-concept study of plamotamab in rheumatoid arthritis, and initiated a Phase 1 study of XmAb657 in idiopathic inflammatory myopathies. The company selected XmAb412 as its lead TL1A x IL23p19 bispecific candidate, paused further development of vudalimab, and decided not to initiate expansion cohorts of XmAb808 in combination with pembrolizumab. Partner updates included FDA approval of Monjuvi in relapsed/refractory follicular lymphoma, positive pivotal results for obexelimab in IgG4-RD and relapsing multiple sclerosis, and Incyte’s expected sBLA filing for first-line DLBCL in the first half of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$110M$228M$41M+ $409M short-term inv.$58M-$202M operating cash flowreport ↗
2023-FY$168M$254M$54M+ $498M short-term inv.$32M$85M operating cash flowreport ↗
2022-FY$165M$200M$54M+ $527M short-term inv.$14M$24M operating cash flowreport ↗
2021-FY$275M$193M$143M+ $154M short-term inv.—-$17M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 21 sales ($7.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-11Cornelissen Bart Jan · SR. VICE PRESIDENT & CFOOpen-market sale10,100$39.82$402KForm 4
2026-11-10RANIERI RICHARD J · directorOption exercise15,000$23.04$346KForm 4
2026-11-10RANIERI RICHARD J · directorOption exercise21,412$26.58$569KForm 4
2026-11-10RANIERI RICHARD J · directorOption exercise11,971$21.31$255KForm 4
2026-11-10RANIERI RICHARD J · directorOption exercise27,372$9.43$258KForm 4
2026-11-10RANIERI RICHARD J · directorOpen-market sale70,080$39.20$2.7MForm 4
2026-11-10RANIERI RICHARD J · directorOpen-market sale11,172$39.59$442KForm 4
2026-11-10RANIERI RICHARD J · directorOption exercise (derivative)15,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 203 reporting institutions held 84.5M shares ($988.9M, 112.5% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.13,035,918$157.2M
2PRIMECAP MANAGEMENT CO/CA/10,338,022$124.7M
3BVF INC/IL7,133,720$86.0M
4RTW INVESTMENTS, LP6,777,461$81.7M
5RA CAPITAL MANAGEMENT, L.P.4,897,237$59.1M
6STATE STREET CORP4,352,036$52.5M
7VANGUARD PORTFOLIO MANAGEMENT LLC3,500,342$42.2M
8VANGUARD CAPITAL MANAGEMENT LLC3,101,647$37.4M
9TCG Crossover Management, LLC2,452,138$29.6M
10EcoR1 Capital, LLC2,183,000$26.3M
11GEODE CAPITAL MANAGEMENT, LLC1,815,577$21.9M
12MORGAN STANLEY1,558,290$18.8M
13DIMENSIONAL FUND ADVISORS LP1,294,887$15.6M
14BAKER BROS. ADVISORS LP1,102,106$13.3M
15UBS Group AG1,082,419$13.1M